InvestorLens

ASND — ASCENDIS PHARMA A/S

Public company

Sign in to save3 tracked investors reported this
For educational research only.InvestorLens analyzes public regulatory filings (SEC EDGAR, STOCK Act PTRs) that may be delayed by 45 days or more. Information shown is historical and is not financial, legal, or tax advice, nor a recommendation or solicitation to buy or sell any security. Always do your own research.

InvestorLens aggregates public filing data to show which tracked investors reported holdings in this stock. Dollar values represent reported position values, not market capitalization, and may be delayed up to 45 days. Not a recommendation.

Sourced from SEC EDGAR public filings

Why are billionaires buying ASND?

Built from public SEC filings and public economic data. Not a recommendation.

Confidence
50
Institutional Conviction
Net distribution · 2 buying vs 2 selling last quarter
34
Macro Tailwind
Macro conditions are mixed for this sector
55
Why? — Evidence & Confidence ▾

Of 4 tracked investors who changed their ASND position last quarter, 2 bought and 2 sold (50% buy-side). Macro conditions are mixed for this sector (Macro Tailwind 55/100 in a Squeeze regime).

Supporting evidence
  • +2 tracked investors added or increased positions last quarter (Izzy Englander, Ken Griffin)
  • +3 tracked investors reported holding ASND at their latest filing
  • +Macro Health is 55/100 in a Squeeze regime — historically acceptable for this sectorsource
Contradicting evidence — always shown
  • −2 tracked investors reduced or exited last quarter (1 reduced, 1 sold out)
  • −13F data is disclosed up to 45 days after quarter end — positions may have changed since
Know the limits
  • · 13F disclosure lag (up to 45 days)
  • · Tracked investors are a sample, not the whole market
  • · Sector regime fit is a historical average, not a guarantee

Every InvestorLens score shows its evidence — including what argues against it. Model conviction-v1 · generated 8/20/2026.

About ASCENDIS PHARMA A/S (ASND)

ASCENDIS PHARMA A/S (ASND) appears in the most recent 13F filings of 3 tracked institutional investors. The largest disclosed position is held by Ken Griffin (Citadel Advisors), valued at $181M. Across recent filings, tracked investors recorded 8 new positions, 11 increased, 18 reduced, and 5 exited. All data sourced from SEC 13F filings.

Smart Money Consensus™

Based on recent institutional activity in ASND

45
/100
Mixed Activity
Added / Increased19
Reduced18
Exited5
BearishBullish
Crowded Trade Score™

How many top investors track ASND

20
/100
Emerging Interest
3investors

A small number of top investors own this.

UndiscoveredCrowded
151015+

ASND Ownership Composition

How ASCENDIS PHARMA A/S is held across tracked investor types, based on reported 13F positions.

Dominant Type
Multi-Strategy / Quant
95% of tracked value
Institutions
3
tracked investors
Total Reported
$206.2M
combined 13F value
Types2
  • Multi-Strategy / Quant95.2%
  • Macro4.8%
Multi-Strategy / Quant(2)
95.2%
Macro(1)
4.8%

Tracked investors currently reporting ASND

3 tracked investors have since exited this position — listed separately below.

  • Ken GriffinJun 30, 2026
    Citadel Advisors
    Shares
    406.8K
    Value
    $108.5M
    % Portfolio
    0.01%
  • Izzy EnglanderJun 30, 2026
    Millennium Management
    Shares
    328.7K
    Value
    $87.7M
    % Portfolio
    0.03%
  • Paul Tudor JonesJun 30, 2026
    Tudor Investment Corp
    Shares
    37.4K
    Value
    $10M
    % Portfolio
    0.01%

Previously held ASND

These investors reported ASND in an earlier quarter but not in their most recent 13F. Figures below are their last reported position, not a current holding.

InvestorFirmLast reported sharesValue thenLast held
Steve CohenPoint72 Asset Management47.8M$70.5MMar 31, 2026
Stanley DruckenmillerDuquesne Family Office158.7K$24.7MMar 31, 2025
Howard MarksOaktree Capital Management1M$1.4MSep 30, 2025

Recent activity

Frequently asked questions

How many institutional investors hold ASND?
3 tracked institutional investors disclosed a position in ASND (ASCENDIS PHARMA A/S) in their most recent 13F filing.
Who is the largest institutional holder of ASND?
Ken Griffin, Citadel Advisors, holds the largest disclosed position in ASND, valued at $181M.
Did institutional ownership of ASND increase or decrease?
Across recent 13F filings, tracked investors recorded 8 new positions, 11 increased, 18 reduced, and 5 fully exited ASND.
Where does this ASND ownership data come from?
SEC Form 13F-HR filings, accessed via EDGAR. 13F filings are disclosed quarterly with a 45-day reporting delay and cover U.S.-listed long equity positions only. This is not investment advice.